Seeking Alpha: Receptos Could Meet With A More Positive Reception

Investors do well to be very skeptical of the biotech companies that go public in the late stages of a multi-year bull market. In many case...

Investopedia: Pfizer Looking A Little Tired

At some point this bull market in all things health care will fade out, and I wonder if Pfizer (NYSE: PFE ) shares will maintain this sort ...

Investopedia: Wall Street Happy To Hum La AbbVie En Rose

For a business that seemed to be oft-maligned when it was still part of Abbott Labs (NYSE: ABT ), AbbVie (Nasdaq: ABBV ) has done pretty ...

Investopedia: Celgene Only Getting Started, But The Street's Already Looking Ahead

Celgene (Nasdaq: CELG ) has been consistently profitable for a while, which is rare enough in the biotech space. What stands out to me wi...

Seeking Alpha: How Bad Will The Partial Hold On Sovaprevir Be For Achillion?

Achillion ( ACHN ) investors got a huge piece of bad news on Monday evening, when this biotech virology specialist announced that its lea...

Seeking Alpha: Volcano Still Has Plenty To Prove

Volcano ( VOLC ) has never been shy about setting ambitious targets or pursuing a bold vision for the company's future. Unfortunately...

Seeking Alpha: Achillion May Be The Most Underrated Biotech Left

There are broadly two types of biotech investors - the Wile E. Coyote types who see bargains everywhere and charge bravely after them and t...